Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Adults with Down syndrome develop the neuropathological hallmarks of Alzheimer's
disease and are at very high risk of developing early-onset dementia, which is now the …
disease and are at very high risk of developing early-onset dementia, which is now the …
Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration
N Gómez de San José, F Massa… - Journal of Neural …, 2022 - Springer
The diagnosis of neurodegenerative disorders is often challenging due to the lack of
diagnostic tools, comorbidities and shared pathological manifestations. Synaptic dysfunction …
diagnostic tools, comorbidities and shared pathological manifestations. Synaptic dysfunction …
The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration
Complement overactivation mediates microglial synapse elimination in neurological
diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD), but how …
diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD), but how …
USP25 inhibition ameliorates Alzheimer's pathology through the regulation of APP processing and Aβ generation
Q Zheng, B Song, G Li, F Cai, M Wu… - The Journal of …, 2022 - Am Soc Clin Investig
Down syndrome (DS), or trisomy 21, is one of the critical risk factors for early-onset
Alzheimer's disease (AD), implicating key roles for chromosome 21–encoded genes in the …
Alzheimer's disease (AD), implicating key roles for chromosome 21–encoded genes in the …
Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives
Alzheimer's disease (AD) is currently constrained by limited clinical treatment options. The
initial pathophysiological event, which can be traced back to decades before the clinical …
initial pathophysiological event, which can be traced back to decades before the clinical …
Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome
Autosomal dominant Alzheimer's disease (ADAD) and Down syndrome (DS) constitute
genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in …
genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in …
Pathologically decreased CSF levels of synaptic marker NPTX2 in DLB are correlated with levels of alpha-synuclein and VGF
Background: Dementia with Lewy bodies (DLB) is a neurodegenerative disease where
synaptic loss and reduced synaptic integrity are important neuropathological substrates …
synaptic loss and reduced synaptic integrity are important neuropathological substrates …
Blood biomarkers for Alzheimer's disease in Down syndrome
Epidemiological evidence suggests that by the age of 40 years, all individuals with Down
syndrome (DS) have Alzheimer's disease (AD) neuropathology. Clinical diagnosis of …
syndrome (DS) have Alzheimer's disease (AD) neuropathology. Clinical diagnosis of …
Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene …
Introduction Synaptic failure, a hallmark of Alzheimer's disease (AD), is correlated with
reduced levels of synaptic proteins. Though people with Down syndrome (DS) are at …
reduced levels of synaptic proteins. Though people with Down syndrome (DS) are at …
Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease
F Massa, C Martinuzzo, N Gómez de San José… - Journal of …, 2024 - Springer
Abstract Background Neuronal pentraxin-2 (NPTX2), crucial for synaptic functioning,
declines in cerebrospinal fluid (CSF) as cognition deteriorates. The variations of CSF NPTX2 …
declines in cerebrospinal fluid (CSF) as cognition deteriorates. The variations of CSF NPTX2 …